Please login to the form below

Not currently logged in

Medmeme appoints Dr Joseph Laudano to medical affairs role

He joins the company from Alliqua Biomedical

Joe LaudanoMedical solutions group Medmeme has appointed Dr Joseph Laudano as vice president, medical affairs strategy.

The role will see Laudano take responsibility for the group’s medical affairs strategies and he will work with the leadership team to create new processes and applications to maximise the utility of the group’s scientific database.

Laudano has over 30 years’ experience in the pharma industry and has previously worked with Alliqua Biomedical where he was vice president of medical affairs, with responsibility for post-marketing clinical trials, publication planning and execution, medical and scientific inquires, medical reviews and developing medical and scientific databases.

He said: “The medical affairs function is in the process of evolving from a traditional support role into a more robust, strategic organisation for data generation and dissemination

“Medmeme’s cutting edge suite of analytical applications is the perfect instrument to help companies drive this transition and I am thrilled to be part of this evolution in this industry.”

Laudano has also held positions for Forest Research Institute as senior director of medical affairs and Roche Laboratories in various medical affairs and marketing positions.

Mahesh Naithani, founder of Medmeme, said: “Medmeme has been going from strength to strength since its inception and now boasts unrivalled access to a wealth of scientific data.

“Joe, with his vast medical affairs experience, will play a vital role in helping us communicate the true value of this data to our customers and in identifying further ways in which we can expand and enhance our unique offering."

26th June 2017

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge